GlassScriptPhysician profile
John A Kallianos
NPI 1245231588
$8,380.67
in general payments reported to CMS, 2019-2025
51 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $1,154 · 2021: $1,236 · 2022: $1,390 · 2023: $1,238 · 2024: $1,308 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,649.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,108.92 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $928.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $705.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $675.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $398.66 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $332.79 | 2019-2024 | |
| Amgen INC. | $267.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $242.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.98 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $209.54 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $200.61 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $187.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.94 | 2020-2025 | Xifaxan |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kallianos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.